Loading
Cancer charities would fund companies to hit specific development milestones, as the cystic fibrosis charity did to create Kalydeco, and take a royalty they reinvest in the next drug.
Disease foundations move from grant-giving to milestone-based development contracts with biotech and pharma: payments are released on defined preclinical and clinical milestones for an agreed indication (for example a rare sarcoma, a paediatric brain tumour, cachexia), the foundation receives royalties or equity, and returns are recycled. The Cystic Fibrosis Foundation's investment in Vertex produced ivacaftor and returned more than $3 billion through a royalty sale; the Leukemia and Lymphoma Society's Therapy Acceleration Program and the Multiple Myeloma Research Foundation have applied versions of this in blood cancers. Solid tumours and paediatric cancers have few such programmes at scale.
Shares A diversified royalty pool that finances academic phase 1 trials across fifty assets, A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, The valley of death between lab and product.
Shares Advance market commitments for paediatric and rare cancer drugs, Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares A non-profit pharmaceutical company for the cancers markets ignore, The valley of death between lab and product, Rare and paediatric cancers without markets.
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares A non-profit pharmaceutical company for the cancers markets ignore, The valley of death between lab and product.
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, The valley of death between lab and product.